Daclahep - Daclatasvir 60 mg Tabs

Daclatasvir belongs to a class of antiviral medications known as NS5A inhibitors, which work by targeting a specific protein that the Hepatitis C virus needs for its replication and assembly. It is typically used in combination with other direct-acting antivirals, such as Sofosbuvir, as part of an interferon-free treatment regimen for chronic HCV infection. This combination approach allows the medication to target the virus from multiple angles, leading to high rates of sustained viral clearance in many patients. Daclatasvir-based regimens are generally taken orally, once daily, over a treatment course that commonly lasts around 12 weeks, though duration may vary based on individual factors. The convenience of oral dosing and shorter treatment courses compared to older Hepatitis C therapies has made these regimens more accessible and easier for patients to complete. Achieving a sustained virologic response, meaning the virus is undetectable in the blood after treatment, is considered a strong indicator of successful cure. Regular monitoring through blood tests helps track viral load and overall treatment progress throughout the course of therapy. Many patients treated with Daclatasvir-based regimens achieve excellent outcomes with high cure rates. As with all antiviral treatments, it should be used under the guidance of a healthcare provider familiar with the patient's specific hepatitis C genotype and health history.